Heart failure and Ca++ activation of the cardiac contractile system: hereditary cardiomyopathy in hamsters (BIO 14.6), isoprenaline overload and the effect of APP 201-533
- PMID: 2821979
- DOI: 10.1007/BF01907020
Heart failure and Ca++ activation of the cardiac contractile system: hereditary cardiomyopathy in hamsters (BIO 14.6), isoprenaline overload and the effect of APP 201-533
Abstract
In the present paper, two experimental models of heart failure, namely hereditary cardiomyopathy in hamsters (BIO 14.6) and cardiac insufficiency due to mild (0.06 microM) isoprenaline overload of rabbit isolated perfused hearts, were compared in terms of resulting alterations at the level of the functionally isolated contractile system of detergent/glycerol treated skinned cardiac fibres. As the main features of Ca activation of tension in these models, the following were found: 1. Within the same species (RB hamsters, BIO 14.6 hamsters or rabbits), the Ca sensitivity, measured as pCa for half maximal Ca activation, was invariably higher in left than in right ventricular skinned fibres. 2. During the development of hereditary cardiomyopathy (BIO 14.6), maximum Ca-activated tension, measured per unit cross-sectional area, was reduced in an age-dependent manner, without any significant reduction in Ca sensitivity. This effect appeared to be more pronounced in left than in right ventricles. 3. In skinned fibres from right or left ventricular papillary muscles from in vitro isoprenaline pretreated rabbit hearts, no significant alteration in the maximum Ca-activated tension (per unit area) was observed in comparison to non-pretreated control hearts, whereas the Ca sensitivity was reduced. Treatment of control or failing heart skinned fibres with cAMP showed no additivity to the Ca desensitization induced by isoprenaline pretreatment. 4. Skinned fibres from isoprenaline pretreated left ventricular rabbit hearts showed a higher susceptibility to the Ca sensitizing effect of APP 201-533 than fibres from unpretreated control hearts. Mild isoprenaline overload and hereditary cardiomyopathy both are forms of heart failure which are presumably not associated with a lack of activator Ca. It is concluded that cardiotonic agents increasing the cardiac myofibrillar sensitivity to Ca ions would be beneficial in both cases, representing a phenomenologically causative treatment in hearts failing due to isoprenaline pretreatment. A main advantage over "classical" cardiotonic agents like cardiac glycosides, beta adrenergic stimulants or phosphodiesterase inhibitors would be the absence of the risk of drug-induced Ca overload.
Similar articles
-
Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.Naunyn Schmiedebergs Arch Pharmacol. 1991 Jul;344(1):90-100. doi: 10.1007/BF00167387. Naunyn Schmiedebergs Arch Pharmacol. 1991. PMID: 1723153
-
EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium.Basic Res Cardiol. 1995 Sep-Oct;90(5):365-71. doi: 10.1007/BF00788497. Basic Res Cardiol. 1995. PMID: 8585857
-
Subsensitivity of the failing human heart to isoprenaline and milrinone is related to beta-adrenoceptor downregulation.J Cardiovasc Pharmacol. 1988 Dec;12(6):726-32. doi: 10.1097/00005344-198812000-00015. J Cardiovasc Pharmacol. 1988. PMID: 2467092
-
Increase in force of contraction by activation of the Na+/Ca(2+)-exchanger in human myocardium.Br J Clin Pharmacol. 1997 Apr;43(4):399-405. doi: 10.1046/j.1365-2125.1997.00581.x. Br J Clin Pharmacol. 1997. PMID: 9146852 Free PMC article.
-
Rabbit models of heart disease.Drug Discov Today Dis Models. 2008 Fall;5(3):185-193. doi: 10.1016/j.ddmod.2009.02.001. Epub 2009 Mar 17. Drug Discov Today Dis Models. 2008. PMID: 32288771 Free PMC article. Review.
Cited by
-
Myofibrillar Ca2+ sensitivity of cardiomyopathic hamster hearts.Pflugers Arch. 1995 Feb;429(4):539-45. doi: 10.1007/BF00704159. Pflugers Arch. 1995. PMID: 7617444
-
In situ study of myofibrils, mitochondria and bound creatine kinases in experimental cardiomyopathies.Mol Cell Biochem. 1994 Apr-May;133-134:287-98. doi: 10.1007/978-1-4615-2612-4_19. Mol Cell Biochem. 1994. PMID: 7808460 Review.
-
New mechanisms for positive inotropic agents: focus on the discovery and development of imazodan.Cardiovasc Drugs Ther. 1989 Mar;3(1):29-42. doi: 10.1007/BF01881527. Cardiovasc Drugs Ther. 1989. PMID: 2487522 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials